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doi:10.1016/j.ejvs.2009.05.006Abstract Objective: To objectively assess the presence of polyvascular disease in patients
with peripheral arterial disease and its relation to inflammation and clinical risk factors.
Methods: A total of 431 vascular surgery patients (mean age 68 years, men 77%) with atheroscle-
rotic diseasewere enrolled. The presence of atherosclerosis was assessed using ultrasonography.
Affected territories were defined as: (1) carotid, stenosis of common or internal carotid artery of
50%, (2) cardiac, left ventricular wall motion abnormalities, (3) abdominal aorta, diameter
30 mm and (4) lower limb, ankleebrachial pressure index <0.9. Cardiovascular risk factors
and high-sensitivity C-reactive protein (hs-CRP) levels were noted in all.
Results: One vascular territorywas affected in 29% of the patients, whereas polyvascular disease
was found in 71%: two affected territories in 45%, three in 23% and four in 3% of patients. Levels of
hs-CRP increased with the number of affected vascular territories (p< 0.001). Multivariable
logistic regression analysis showed age 70 years, male gender, body mass index
(BMI) 25 kg m2, and hs-CRP to be independently associated with polyvascular disease.
Conclusion: Polyvascular disease is a commoncondition in patientswhohaveundergone vascular
surgery. The level of systemic inflammation, reflected by hs-CRP levels, ismoderately associated
with the extent of polyvascular disease.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.10 4634613; fax: þ31 10
smusmc.nl (D. Poldermans).
ty for Vascular Surgery. PublisheAtherosclerosis is a chronic inflammatory disease that can
affect different vascular territories focally. However, the
presence of atherosclerosis in one vascular territory
generally denotes the presence of the disease in other
vascular territories, giving it a character of systemic and
generalised disease. Coincidence of atherosclerotic diseased by Elsevier Ltd. All rights reserved.
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population in question but also on the criteria and methods
used to assess the diagnosis. Recently published results of
Reduction of Atherothrombosis for Continued Health
(REACH) registry showed that patients with atherosclerotic
disease in more than one vascular territory have worse
long-term outcome.1 However, the definition of poly-
vascular disease (PVD) was based on relatively subjective
criteria.
Ultrasonography is a highly effective and reliable
modality for the detection of atherosclerotic disease.2
Ultrasound can measure both anatomy and function, and
provides well-validated surrogate markers for atheroscle-
rosis, such as carotid intimaemedia complex thickness,
ankleebrachial pressure index (ABI), left ventricular wall
motion abnormalities and diameter of blood vessels. The
role of inflammation in the pathogenesis of atherosclerosis
raised the interest in identifying inflammatory markers
related to the progress and extent of atherosclerotic
disease. It has been shown that levels of C-reactive protein
(CRP) increase in patients with coronary artery disease
(CAD) and peripheral arterial disease.3e6
The current study aims to determine objectively the
prevalence of PVD atherosclerosis in patients who have
undergone vascular surgery, using ultrasonography and to
determine whether there are differences in inflammatory
activity related to the presence and extent of (a)symp-
tomatic PVD.
Methods
Study population
The study population composed of 431 patients with known
peripheral arterial disease who were referred to the
department of vascular surgery of the Erasmus Medical
Centre, Rotterdam, the Netherlands, in the period between
March 2006 and September 2007. Patients with (1) a symp-
tomatic carotid artery stenosis or (2) intermittent claudi-
cation (including those with rest or night pain) or (3)
patients referred because of a recently discovered
abdominal aortic aneurysm were eligible for the study. The
hospital’s ethics committee approved the study and all
patients gave informed consent.
Cardiovascular risk factors
Patients were screened for the following cardiovascular risk
factors: age, gender, hypertension (previously diagnosed or
blood pressure 140/90 mmHg measured on the day of first
visit) or anti-hypertensive therapy, renal failure (serum
creatinine >2 mg dl1), diabetes mellitus (fasting glucose
level of 7.0 mmol l1, or treatment with oral medications
or insulin), hypercholesterolaemia (total cholesterol
>200 mg dl1 and/or low-density lipoprotein (LDL)
>100 mg dl1 and/or current statin therapy) and current or
former smoking. In addition, established CAD (angina pec-
toris, myocardial infarction (MI), heart failure and previous
coronary revascularization) was noted. Additionally, in
all patients, serum level of high-sensitivity (hs)-CRP
was determined by a nephelometric assay ona Beckman-Immage analyzer (Beckman-Coulter, Fullerton,
California, USA).
Establishment of number of affected arterial
territories
For the identification of asymptomatic atherosclerotic
lesions (i.e., atherosclerotic lesion which was not sus-
pected or diagnosed previously), we performed a duplex
scan of the carotid arteries, echocardiography, ultrasono-
graphic measurement of infrarenal abdominal aortic
diameter and we measured the ABI. The examinations were
performed and reviewed by two physicians, both skilled and
experienced in ultrasonography. They were unaware of the
referral diagnosis and previous medical history.
Carotid ultrasound imaging
Ultrasound images of the common, bifurcation and internal
segments of each carotid artery were acquired in every
patient. The common carotid artery segment was defined
as the distal 1 cm of the common carotid artery, immedi-
ately before the origin of the bulb. The bifurcation segment
was defined as the distal 1 cm of the bulb, where the flow
divider between internal and external carotid artery is
present. The internal carotid artery segment was defined as
the proximal 1 cm of the internal carotid artery, starting
immediately beyond the flow divider. Carotid ultrasound
imaging was directed to the measurement of carotid
intimaemedia complex thickness (CIMT) and identification
of the atherosclerotic plaques in each of the six observed
carotid segments. Atherosclerotic plaques were defined as
an echogenic thickening of intimal reflection that
encroaches on the arterial lumen, with a minimal
CIMT 1.2 mm.7 The plaque was considered significant if it
causes the narrowing of common or internal carotid artery
by 50%, according to Doppler US criteria proposed by
the Society of Radiologists in Ultrasound Consensus
Conference.8 Examinations were performed with a portable
device, Acuson Cypress (Acuson, Mountain View, CA), using
5.4e6.6-MHz linear transducer.
Cardiac ultrasound imaging
CAD was diagnosed previously in 166 patients: in 93 (56%) by
coronary angiography, in 46 (28%) by dobutamine stress
echocardiography (DSE) and in 27 (16%) by radionuclide
myocardial perfusion scanning. In another 265 (61%)
patients without previous diagnosis, but with high proba-
bility for presence of CAD, we performed echocardiography
by the protocol described elsewhere.9 Appearance of left
ventricular wall motion abnormalities during the test was
considered suggestive for the presence of CAD.
Abdominal aortic ultrasound imaging
Using the portable Acuson Cypress (Acuson, Mountain View,
CA) with 1.8e3.6-MHz curveelinear transducer, the ultra-
sound examination was focussed on the identification of the
infrarenal aorta. The measurement of its maximal diameter
was obtained using on-screen callipers between the two
edges of the aortic wall, including intraluminal thrombus, if
present. The probe was maintained perpendicular to the
aortic blood flow determined by the colour Doppler to yield
orthogonal sections of the aorta. Measurements were taken
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maximal obtained diameter in any direction, expressed in
millimetres, was used for analysis. A measured diameter of
30 mm was considered as abnormal.
ABI measurement
TheABI in the right and left legwas calculated by dividing the
right and the left ankle pressure by the brachial pressure
after obtaining systolic blood pressures in the right and left
brachial artery, right and left dorsalis pedis artery and right
and left posterior tibial artery. The higher of the two systolic
brachial blood pressures, as well as the higher of the systolic
blood pressures in the dorsalis pedis and posterior tibial
artery was used for calculating the ABI. The ABI was
measured after the participants had been resting in the
supine position for at least 10 min. Of theABI values obtained
in each leg, the lower was used in all the analyses. An ABI of
<0.90 was considered abnormal. ABIs were measured using
Doppler ultrasonic instrument Imexdop CTþ (Miami Medical,
Glen Allen, VA, USA) with 8-MHz vascular probe.
Statistical analysis
Continuous data are expressed as mean (SD) or median
(range) and compared using the student’s t-test, one-way
analysis of variance (ANOVA) or ManneWhitney U-test when
appropriate. Categorical data are presented as percent
frequencies and differences between proportions were
compared using the chi-square test. Receiver-operating
characteristic curve analysis was used to determine the
optimal cut-off value of the hs-CRP consistent with the pres-
ence of atherosclerotic changes in >1 vascular territory.
Applied multivariable logistic regression analysis was used in
twomodels to calculate the likelihoodof thepresence ofPVD.
The variables included in thefirstmodelwere: age 70years,
gender, BMI 25 kgm2, hypertension, dyslipidaemia, dia-
betes mellitus, renal failure and smoking. In the second
model,weaddedhs-CRP to the other variables included in the
first model. The performances of both models were studied
with respect to discrimination and calibration. Discrimination
refers to the ability to distinguish patients with and without
PVD; it was quantified by C-statistic. Calibration refers toTable 1 Baseline characteristics of study population.
Total Ind
nZ 431 Car
nZ
Age (years; SD) 68 10 68
Men 332 (77%) 68
BMI (kg m2; SD) 26 4 26
History of cerebrovascular disease 155 (36%) 103
History of coronary artery disease 172 (40%) 31
Heart failure 42 (10%) 4 (4
Hypertension 335 (78%) 87
Diabetes mellitus 96 (22%) 26
Dyslipidaemia 326 (76%) 78
Renal failure 71 (17%) 8 (8
Current or former smoking 274 (64%) 60whether the predictedprobability of PVD is in agreementwith
the observedprobability andwasmeasuredwith theHosmere
Lemeshow goodness-of-fit test. All statistical analyses were
performed using SPSS 14.0 (SPSS Inc., Chicago, IL, USA).
Results
A total of 431 patients were included in the study. Their
mean age was 68 years and 77% were male. Symptomatic
carotid artery disease was the referral diagnosis in 103/431
(24%) patients, an abdominal aortic aneurysm in 170/431
(39%) and symptomatic lower extremity arterial disease in
158/431 (37%). The clinical baseline characteristics of these
patients are listed in Table 1.
Prevalence of PVD
A total of 213/431 patients with peripheral arterial disease
were known to have PVD, that is, multiple affected arterial
territories, based on clinical history and indication for
referral to only a vascular surgery outpatient clinic. The
routine screening of the other vascular territories using
ultrasound revealed an additional 91 patients with previ-
ously unknown PVD. Importantly, in patients with already-
known multiple affected arterial territories, there was an
underestimation of the true number of affected territories;
of 170 patients with two clinically apparent affected
territories, there were 43 (25%) and 7 (4%) with three or
four affected territories, respectively, when standard
ultrasound screening was used.
Based on the ultrasound measurements, 127/431 (29%)
patients had only one affected arterial territory, 193/431
(45%) had two affected territories, 99/431 (23%) had three
affected arterial territories and 12/431 (3%) had four
affected arterial territories.
Asymptomatic atherosclerotic disease in at least one
vascular territory other than the referral territory was
present in 30/103 (29%) patients initially presented with
symptomatic carotid artery disease, in 65/170 (38%)
patients with an abdominal aortic aneurysm and in 62/158
(39%) patients with symptomatic lower extremity arterial
disease.ex territory p-Value
otid AAA LEAD
103 nZ 170 nZ 158
10 71 8 65 11 <0.001
(66%) 152 (89%) 112 (71%) <0.001
4 25 4 26 4 NS
(100%) 27 (16%) 25 (16%) <0.001
(30%) 83 (49%) 58 (37%) 0.006
%) 29 (17%) 9 (6%) <0.001
(85%) 132 (78%) 116 (73%) NS
(25%) 27 (16%) 43 (27%) 0.034
(76%) 129 (76%) 119 (76%) NS
%) 39 (23%) 24 (15%) 0.004
(58%) 113 (67%) 101 (64%) NS
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artery tree as this was found to be asymptomatically
present in 82/431 (19%) patients. Asymptomatic carotid
artery disease, abdominal aortic aneurysm and asymptom-
atic lower extremity peripheral arterial disease
were present in 14 (3%), 33 (8%) and 38 (9%) patients,
respectively. The prevalence of concomitant atheroscle-
rotic lesions, both symptomatic and asymptomatic, among
patients with different referral diagnoses is shown in Fig. 1.
PVD and cardiovascular risk factors and
inflammation
As is shown in Table 2, when all cardiovascular risk factors
were evaluated in a logistic regression analysis only ageFigure 1 Prevalence of previously known and asymptomatic
atherosclerotic lesions in patients initially presented with
ECAD (A), AAA (B), and LEAD (C). ECAD e extra-cranial arterial
disease; AAA e abdominal aortic aneurysm; LEAD e lower
extremity arterial disease; CAD e coronary artery disease.70 years, renal failure, male gender and BMI 25 kgm2,
were independently associated with the presence of PVD.
As is shown in Fig. 2, the median values of hs-CRP differed
among the patients with respect to the number of vascular
territories affected by atherosclerosis. Using receiver-
operating characteristic curve analysis, the optimal cut-off
value of the hs-CRP levels to predict the presence of PVD
was 3.60 mg l1 (area under the curve 0.68). When hs-CRP is
added as a dichotomous variable (i.e., below or above
3.60 mg l1) to clinical cardiovascular risk factors, it
appears to be a strong predictor for the presence of PVD
(OR 3.81, 95% CI 2.39e6.09; Table 2).Discussion
This study assessed the prevalence of PVD and its rela-
tionship with cardiovascular risk factors and hs-CRP. In
patients with one symptomatic arterial territory, athero-
sclerotic disease in other arterial territories was common,
with over two-thirds of these patients having more than one
affected site. Importantly, when relying only on clinical
history, 35% of patients would have been misclassified as
having only one affected arterial territory. Furthermore,
hs-CRP showed a close relationship with the number of
affected vascular territories and increased gradually with
every additional vascular territory affected.
Atherosclerosis is a complex and progressive disease that
affects medium- and large-sized arteries diffusely, and
involves gradual accumulation of lipids, inflammatory cells
and fibrous elements in the vessel walls.10 Besides,
atherosclerosis is caused by the same pathological
processes regardless of the vascular territory involved and
it displays heterogeneity in space and time. Atherosclerosis
affects certain sites in the arterial tree preferentially,
particularly areas exposed to low shear stress, oscillatory or
turbulent blood flow, like points of branching and curva-
tures.11 Importantly, atherosclerosis in each vascular
territory is predisposed by the same cardiovascular risk
factors, such as dyslipidaemia, diabetes mellitus, obesity,
hypertension or smoking.12 Interaction between them is
always present, and usually it is additive. In our study,
older age, male gender and BMI 25 kgm2 were strongly
associated with the presence of PVD.
It has been suggested that inflammation plays a pivotal
role in atherosclerosis. High-sensitivity C-reactive protein
is a non-specific biomarker of inflammation. Recent large-
scale population-based studies have shown that elevated
levels of hs-CRP are associated with an increased risk for
future cardiovascular events in both patients with or
without manifest atherosclerotic disease.13 As was
recently shown in the Rotterdam study, CRP is associated
with both extent and progression of atherosclerotic
disease in different vascular territories.14,15 These findings
were confirmed in the present study. Whether the
increased inflammatory activity in patients with poly-
vascular disease is the causative mechanism for the
development of polyvascular disease, or that it is merely
caused by the increased number of affected vessels,
remains unknown.
The concomitant occurrence in different vascular terri-
tories is a characteristic feature of atherosclerotic disease.
Table 2 Association between cardiovascular risk factors þ high-sensitivity CRP and polyvascular disease.
Univariate analysis Model 1 Model 2 Model 3
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age 70 years 1.59 1.05e2.42 1.80 1.14e2.85 1.77 1.10e2.85 1.77 1.10e2.85
Male gender 3.04 1.89e4.81 2.68 1.63e4.41 2.61 1.54e4.41 2.60 1.54e4.41
BMI 25 kg m2 2.85 1.86e4.37 2.69 1.70e4.24 2.39 1.49e3.85 2.40 1.50e3.85
Hypertension 1.34 0.83e2.18 1.06 0.62e1.81 1.11 0.63e1.95 1.11 0.63e1.95
Diabetes mellitus 1.65 0.97e2.83 1.35 0.76e2.42 1.34 0.73e2.45 1.34 0.73e2.45
Dyslipidaemia 1.43 0.89e2.28 1.22 0.73e2.04 1.10 0.64e1.88 1.10 0.64e1.88
Renal failure 2.07 1.09e3.93 1.53 0.77e3.05 1.58 0.77e3.24 1.58 0.77e3.24
Current or former smoking 1.31 0.86e2.01 1.27 0.79e2.03 1.27 0.78e2.07 1.27 0.78e2.07
hs-CRP (continuous)a 1.25 1.15e1.37 e e 1.24 1.13e1.36 e e
Hs-CRP 3.60 mg l1 4.22 2.71e6.56 e e e 3.81 2.39e6.09
C-index 0.72 0.77 0.78
BMIZ body mass index; hs-CRPZ high-sensitivity C-reactive protein; ORZ odds ratio; CIZ confidence interval.
Model 1 included risk factors only, model 2 risk factors and hs-CRP as continuous variable (as increment of 1 mg l1), and model 3 risk
factors and hs-CRP as binary variable (lower or higher than the cut-off value of 3.60 mg l1).
a As increment of 1 mg l1.
Polyvascular Disease in Vascular Surgery Patients 439The generalised nature of atherosclerosis was well shown in
several previously published studies. Of almost 20 000
patients with peripheral, carotid and coronary atheroscle-
rotic disease included in the Clopidogrel Versus Aspirin in
Patients at Risk for Ischemic Events (CAPRIE) trial, about
23% had symptomatic disease in two, and 3% in all three
vascular territories.16 Symptomatic PVD was also common
in the REACH registry, which includes more than 67 000
patients from 44 countries around the world.17 One of six
patients with either coronary, cerebrovascular or periph-
eral arterial disease had symptomatic involvement of one
or two other arterial beds, giving the overall prevalence of
PVD to be almost 16%. The 1-year major event rates
(cardiovascular death, MI, or stroke or hospitalisation forh
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Figure 2 Relationship between the levels of hs-CRP and
number of affected vascular beds. Middle horizontal line,
median; box, 1 standard deviation; brackets, 95% confidence
interval. hs-CRPZ high-sensitivity C-reactive protein.atherothrombotic events) among the REACH registry
patients increased markedly with the number of symp-
tomatic arterial disease locations, ranging from 12.58% for
patients with one to 21.14% with two and 26.27% for
patients with three symptomatic arterial disease locations
(p< 0.001 for trend).1 The REACH registry investigators
pointed out that those results might in fact underestimate
the impact of peripheral arterial disease because the
degree of overlap in the involvement of the different
arterial territories would be even greater if the degree of
asymptomatic disease were examined. In the current study,
we performed extensive non-invasive screening for
atherosclerotic disease in four vascular territories, in
patients with at least one symptomatic territory. Indeed,
using this extensive work, we found a much higher preva-
lence of PVD compared to the REACH registry data.
In conclusion, the prevalence of PVD in patients with
symptomatic peripheral arterial disease is high. System-
atical screening of patients with peripheral arterial disease
using ultrasound modalities significantly increases the
number of patients with PVD. Based on the outcome of
the REACH registry, these patients might deserve a more
aggressive medical treatment regimen since their risk for
future cardiovascular events is high.Acknowledgements
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